Allergen-controlled study of intranasal immunotherapy for ragweed hay fever

P. W. Welsh, J. H. Butterfield, J. W. Yunginger, M. K. Agarwal, G. J. Gleich

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Previous studies of intranasal immunotherapy have not included control groups treated with an irrelevant allergen. In the present double-blind study, we tested the effectiveness of intranasal immunotherapy in 20 patients sensitive to both short ragweed (SRW) and orchard grass (OG). Patients sprayed increasing concentrations of either SRW (n = 11) or OG (n = 9) extract intranasally six times per day for 8 wk before the SRW pollination season. The effects of this treatment were determined by analysis of symptom score diaries and clinical examinations during the SRW pollination season. SRW-treated patients received cumulative AgE doses from 3 to 59 μg (mean 21); this mean dose was approximately sevenfold less than that used in a previous study from our laboratory. All patients reported immediate hay fever symptoms after use of the nasal spray. Five patients (four SRW- and one OG-treated) reported episodes of mild epistaxis during treatment; no other unexpected side effects were noted. During the treatment period, more SRW-treated patients showed signs of nasal obstruction and edematous nasal mucosa than OG-treated control patients (p < 0.03). During the SRW pollination season, the SRW-treated patients reported lower mean weekly symptom scores than the OG-treated control patients, but the difference was not statistically significant. Supplemental antihistamine use was significantly higher (p < 0.016) in the OG-treated control patients during the SRW pollination period. Subjective assessment of treatment efficacy by patients was similar in both treatment groups. We conclude that intranasal immunotherapy was of only marginal benefit in this study.

Original languageEnglish (US)
Pages (from-to)454-460
Number of pages7
JournalThe Journal of allergy and clinical immunology
Volume71
Issue number5
DOIs
StatePublished - 1983

Fingerprint

Ambrosia
Seasonal Allergic Rhinitis
Immunotherapy
Allergens
Dactylis
Pollination
Nasal Sprays
Nasal Obstruction
Epistaxis
Nasal Mucosa
Histamine Antagonists
Therapeutics
Double-Blind Method

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Welsh, P. W., Butterfield, J. H., Yunginger, J. W., Agarwal, M. K., & Gleich, G. J. (1983). Allergen-controlled study of intranasal immunotherapy for ragweed hay fever. The Journal of allergy and clinical immunology, 71(5), 454-460. https://doi.org/10.1016/0091-6749(83)90461-X

Allergen-controlled study of intranasal immunotherapy for ragweed hay fever. / Welsh, P. W.; Butterfield, J. H.; Yunginger, J. W.; Agarwal, M. K.; Gleich, G. J.

In: The Journal of allergy and clinical immunology, Vol. 71, No. 5, 1983, p. 454-460.

Research output: Contribution to journalArticle

Welsh, P. W. ; Butterfield, J. H. ; Yunginger, J. W. ; Agarwal, M. K. ; Gleich, G. J. / Allergen-controlled study of intranasal immunotherapy for ragweed hay fever. In: The Journal of allergy and clinical immunology. 1983 ; Vol. 71, No. 5. pp. 454-460.
@article{206dddd332d1445d9e0c8bf7ed26cda3,
title = "Allergen-controlled study of intranasal immunotherapy for ragweed hay fever",
abstract = "Previous studies of intranasal immunotherapy have not included control groups treated with an irrelevant allergen. In the present double-blind study, we tested the effectiveness of intranasal immunotherapy in 20 patients sensitive to both short ragweed (SRW) and orchard grass (OG). Patients sprayed increasing concentrations of either SRW (n = 11) or OG (n = 9) extract intranasally six times per day for 8 wk before the SRW pollination season. The effects of this treatment were determined by analysis of symptom score diaries and clinical examinations during the SRW pollination season. SRW-treated patients received cumulative AgE doses from 3 to 59 μg (mean 21); this mean dose was approximately sevenfold less than that used in a previous study from our laboratory. All patients reported immediate hay fever symptoms after use of the nasal spray. Five patients (four SRW- and one OG-treated) reported episodes of mild epistaxis during treatment; no other unexpected side effects were noted. During the treatment period, more SRW-treated patients showed signs of nasal obstruction and edematous nasal mucosa than OG-treated control patients (p < 0.03). During the SRW pollination season, the SRW-treated patients reported lower mean weekly symptom scores than the OG-treated control patients, but the difference was not statistically significant. Supplemental antihistamine use was significantly higher (p < 0.016) in the OG-treated control patients during the SRW pollination period. Subjective assessment of treatment efficacy by patients was similar in both treatment groups. We conclude that intranasal immunotherapy was of only marginal benefit in this study.",
author = "Welsh, {P. W.} and Butterfield, {J. H.} and Yunginger, {J. W.} and Agarwal, {M. K.} and Gleich, {G. J.}",
year = "1983",
doi = "10.1016/0091-6749(83)90461-X",
language = "English (US)",
volume = "71",
pages = "454--460",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Allergen-controlled study of intranasal immunotherapy for ragweed hay fever

AU - Welsh, P. W.

AU - Butterfield, J. H.

AU - Yunginger, J. W.

AU - Agarwal, M. K.

AU - Gleich, G. J.

PY - 1983

Y1 - 1983

N2 - Previous studies of intranasal immunotherapy have not included control groups treated with an irrelevant allergen. In the present double-blind study, we tested the effectiveness of intranasal immunotherapy in 20 patients sensitive to both short ragweed (SRW) and orchard grass (OG). Patients sprayed increasing concentrations of either SRW (n = 11) or OG (n = 9) extract intranasally six times per day for 8 wk before the SRW pollination season. The effects of this treatment were determined by analysis of symptom score diaries and clinical examinations during the SRW pollination season. SRW-treated patients received cumulative AgE doses from 3 to 59 μg (mean 21); this mean dose was approximately sevenfold less than that used in a previous study from our laboratory. All patients reported immediate hay fever symptoms after use of the nasal spray. Five patients (four SRW- and one OG-treated) reported episodes of mild epistaxis during treatment; no other unexpected side effects were noted. During the treatment period, more SRW-treated patients showed signs of nasal obstruction and edematous nasal mucosa than OG-treated control patients (p < 0.03). During the SRW pollination season, the SRW-treated patients reported lower mean weekly symptom scores than the OG-treated control patients, but the difference was not statistically significant. Supplemental antihistamine use was significantly higher (p < 0.016) in the OG-treated control patients during the SRW pollination period. Subjective assessment of treatment efficacy by patients was similar in both treatment groups. We conclude that intranasal immunotherapy was of only marginal benefit in this study.

AB - Previous studies of intranasal immunotherapy have not included control groups treated with an irrelevant allergen. In the present double-blind study, we tested the effectiveness of intranasal immunotherapy in 20 patients sensitive to both short ragweed (SRW) and orchard grass (OG). Patients sprayed increasing concentrations of either SRW (n = 11) or OG (n = 9) extract intranasally six times per day for 8 wk before the SRW pollination season. The effects of this treatment were determined by analysis of symptom score diaries and clinical examinations during the SRW pollination season. SRW-treated patients received cumulative AgE doses from 3 to 59 μg (mean 21); this mean dose was approximately sevenfold less than that used in a previous study from our laboratory. All patients reported immediate hay fever symptoms after use of the nasal spray. Five patients (four SRW- and one OG-treated) reported episodes of mild epistaxis during treatment; no other unexpected side effects were noted. During the treatment period, more SRW-treated patients showed signs of nasal obstruction and edematous nasal mucosa than OG-treated control patients (p < 0.03). During the SRW pollination season, the SRW-treated patients reported lower mean weekly symptom scores than the OG-treated control patients, but the difference was not statistically significant. Supplemental antihistamine use was significantly higher (p < 0.016) in the OG-treated control patients during the SRW pollination period. Subjective assessment of treatment efficacy by patients was similar in both treatment groups. We conclude that intranasal immunotherapy was of only marginal benefit in this study.

UR - http://www.scopus.com/inward/record.url?scp=0020640969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020640969&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(83)90461-X

DO - 10.1016/0091-6749(83)90461-X

M3 - Article

C2 - 6601670

AN - SCOPUS:0020640969

VL - 71

SP - 454

EP - 460

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 5

ER -